SLC5A2 and COVID-19: If sodium-glucose cotransporter-2 inhibitors such as dapagliflozin and empagliflozin are used as an oral anti-diabetic treatment in diabetic patients with COVID-19, they may aggravate the disease due to volume reduction 31.